Hepatitis E in developed countries: Current status and future perspectives

Future Microbiology

Volumn 9, Issue 12, 2014, Pages 1361-1372

  Dalton, Harry R ^a   Kamar, Nassim ^b,c,d   Izopet, Jacques ^c,d  

^a UNIVERSITY OF EXETER MEDICAL SCHOOL   (United Kingdom)

^b CHU RANGUEIL   (France)

^c CHU PURPAN   (France)

^d UNIVERSITÉ PAUL SABATIER   (France)

Author keywords

chronic infection; cirrhosis; hepatitis; hepatitis E; pigs; zoonosis

Indexed keywords

CALCINEURIN INHIBITOR; MYCOPHENOLIC ACID; PEGINTERFERON; RIBAVIRIN; TACROLIMUS;

ANEMIA; CLINICAL FEATURE; DEVELOPED COUNTRY; GENOTYPE; HEPATITIS E; HEPATITIS E VIRUS; HUMAN; INFECTION; LABORATORY; MUSCLE ATROPHY; NEUROLOGIC DISEASE; NONHUMAN; PHENOTYPE; REVIEW; SWINE; ZOONOSIS; ACUTE DISEASE; ANIMAL; CHRONIC DISEASE; COMPLICATION; DEVELOPING COUNTRY; FEMALE; GENETICS; MALE; NERVOUS SYSTEM DISEASES; PIG; VIROLOGY;

HEPATITIS E VIRUS; SUIDAE; SUS;

ACUTE DISEASE; ANIMALS; CHRONIC DISEASE; DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; FEMALE; GENOTYPE; HEPATITIS E; HEPATITIS E VIRUS; HUMANS; MALE; NERVOUS SYSTEM DISEASES; SWINE; ZOONOSES;

EID: 84919785237     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.14.89     Document Type: Review

References (85)

1. Holla RP, Ahmad I, Ahmad Z, Jameel S. Molecular virology of hepatitis E virus. Semin. Liver. Dis. 33(1), 3-14 (2013).
2. Koonin EV, Gorbalenya AE, Purdy MA, Rozanov MN, Reyes GR, Bradley DW. Computer-assisted assignment of functional domains in the nonstructural polyprotein of hepatitis E virus: delineation of an additional group of positive-strand RNA plant and animal viruses. Proc. Natl Acad. Sci. USA 89(17), 8259-8263 (1992).
3. Lhomme S, Garrouste C, Kamar N et al. Influence of polyproline region and macro domain genetic heterogeneity on HEV persistence in immunocompromised patients. J. Infect. Dis. 209(2), 300-303 (2014).
4. Nguyen HT, Torian U, Faulk K et al. A naturally occurring human/hepatitis E recombinant virus predominates in serum but not in faeces of a chronic hepatitis E patient and has a growth advantage in cell culture. J. Gen. Virol. 93(Pt 3), 526-530 (2012).
5. Purdy MA, Lara J, Khudyakov YE. The hepatitis E virus polyproline region is involved in viral adaptation. PLoS ONE 7(4), e35974 (2012).
6. Shukla P, Nguyen HT, Faulk K et al. Adaptation of a genotype 3 hepatitis E virus to efficient growth in cell culture depends on an inserted human gene segment acquired by recombination. J. Virol. 86(10), 5697-5707 (2012).
7. Shukla P, Nguyen HT, Torian U et al. Cross-species infections of cultured cells by hepatitis E virus and discovery of an infectious virus-host recombinant. Proc. Natl Acad. Sci. USA 108(6), 2438-2443 (2011).
8. Johne R, Reetz J, Ulrich RG et al. AnORF1-rearranged hepatitis E virus derived from a chronically infected patient efficiently replicates in cell culture. J. Viral Hepat. 21(6), 447-456 (2014).
9. Purdy MA. Evolution of the hepatitis E virus polyproline region: order from disorder. J. Virol. 86(18), 10186-10193 (2012).
10. Tang X, Yang C, Gu Y et al. Structural basis for the neutralization and genotype specificity of hepatitis E virus. Proc. Natl Acad. Sci. USA 108(25), 10266-10271 (2011).
11. Xing L, Li TC, Mayazaki N et al. Structure of hepatitis E virion-sized particle reveals an RNA-dependent viral assembly pathway. J. Biol. Chem. 285(43), 33175-33183 (2010).
12. Emerson SU, Nguyen HT, Torian U, Burke D, Engle R, Purcell RH. Release of genotype 1 hepatitis E virus from cultured hepatoma and polarized intestinal cells depends on open reading frame 3 protein and requires an intact PXXP motif. J. Virol. 84(18), 9059-9069 (2010).
13. Yamada K, Takahashi M, Hoshino Y et al. ORF3 protein of hepatitis E virus is essential for virion release from infected cells. J. Gen. Virol. 90(Pt 8), 1880-1891 (2009).
14. Nagashima S, Takahashi M, Jirintai et al. A PSAP motif in the ORF3 protein of hepatitis E virus is necessary for virion release from infected cells. J. Gen. Virol. 92(Pt 2), 269-278 (2011).
15. Feng Z, Lemon SM. Peek-a-boo: membrane hijacking and the pathogenesis of viral hepatitis. Trends Microbiol. 22(2), 59-64 (2014).
16. Takahashi M, Tanaka T, Takahashi H et al. Hepatitis E Virus (HEV) strains in serum samples can replicate efficiently in cultured cells despite the coexistence of HEV antibodies: characterization of HEV virions in blood circulation. J. Clin. Microbiol. 48(4), 1112-1125 (2010).
17. Rogee S, Talbot N, Caperna T, Bouquet J, Barnaud E, Pavio N. New models of hepatitis E virus replication in human and porcine hepatocyte cell lines. J. Gen. Virol. 94(Pt 3), 549-558 (2013).
18. Yunoki M, Yamamoto S, Tanaka H et al. Extent of hepatitis E virus elimination is affected by stabilizers present in plasma products and pore size of nanofilters. Vox sang. 95(2), 94-100 (2008).
19. Krawczynski K, Meng XJ, Rybczynska J. Pathogenetic elements of hepatitis E and animal models of HEV infection. Virus Res. 161(1), 78-83 (2011).
20. Aggarwal R, Kamili S, Spelbring J, Krawczynski K. Experimental studies on subclinical hepatitis E virus infection in cynomolgus macaques. J. Infect. Dis. 184(11), 1380-1385 (2001).
21. Mao J, Zhao Y, She R et al. Detection and localization of rabbit hepatitis e virus and antigen in systemic tissues from experimentally intraperitoneally infected rabbits. PLoS ONE 9(3), e88607 (2014).
22. Williams TP, Kasorndorkbua C, Halbur PG et al. Evidence of extrahepatic sites of replication of the hepatitis E virus in a swine model. J. Clin. Microbiol. 39(9), 3040-3046 (2001).
23. Barnaud E, Rogee S, Garry P, Rose N, Pavio N. Thermal inactivation of infectious hepatitis E virus in experimentally contaminated food. Appl. Environ. Microbiol. 78(15), 5153-5159 (2012).
24. Kalia M, Chandra V, Rahman SA, Sehgal D, Jameel S. Heparan sulfate proteoglycans are required for cellular binding of the hepatitis E virus ORF2 capsid protein and for viral infection. J. Virol. 83(24), 12714-12724 (2009).
25. Kapur N, Thakral D, Durgapal H, Panda SK. Hepatitis E virus enters liver cells through receptor-dependent clathrin-mediated endocytosis. J. Viral. Hepat. 19(6), 436-448 (2012).
26. Meng XJ. Zoonotic and foodborne transmission of hepatitis E virus. Semin. Liver. Dis. 33(1), 41-49 (2013).
27. Smith DB, Purdy MA, Simmonds P. Genetic variability and the classification of hepatitis E virus. J. Virol. 87(8), 4161-4169 (2013).
28. Izopet J, Dubois M, Bertagnoli S et al. Hepatitis E virus strains in rabbits and evidence of a closely related strain in humans, France. Emerging Infect. Dis. 18(8), 1274-1281 (2012).
29. Lu L, Li C, Hagedorn CH. Phylogenetic analysis of global hepatitis E virus sequences: genetic diversity, subtypes and zoonosis. Rev. Med. Virol. 16(1), 5-36 (2006).
30. Kamar N, Dalton HR, Abravanel F, Izopet J. Hepatitis E virus infection. Clin. Microbiol. Rev. 27(1), 116-138 (2014).
31. Colson P, Romanet P, Moal V et al. Autochthonous infections with hepatitis E virus genotype 4, France. Emerging Infect. Dis. 18(8), 1361-1364 (2012).
32. Bouquet J, Tesse S, Lunazzi A et al. Close similarity between sequences of hepatitis E virus recovered from humans and swine, France, 2008-2009. Emerging Infect. Dis. 17(11), 2018-2025 (2011).
33. Legrand-Abravanel F, Mansuy JM, Dubois M et al. Hepatitis E virus genotype 3 diversity, France. Emerging Infect. Dis. 15(1), 110-114 (2009).
34. Colson P, Borentain P, Queyriaux B et al. Pigliver sausage as a source of hepatitis E virus transmission to humans. J. Infect. Dis. 202(6), 825-834 (2010).
35. Feagins AR, Opriessnig T, Guenette DK, Halbur PG, Meng XJ. Detection and characterization of infectious Hepatitis E virus from commercial pig livers sold in local grocery stores in the USA. J. Gen. Virol. 88(Pt 3), 912-917 (2007).
36. Mansuy JM, Bendall R, Legrand-Abravanel F et al. Hepatitis E virus antibodies in blood donors, France. Emerging Infect. Dis. 17(12), 2309-2312 (2011).
37. Wichmann O, Schimanski S, Koch J et al. Phylogenetic and case-control study on hepatitis E virus infection in Germany. J. Infect. Dis. 198(12), 1732-1741 (2008).
38. Legrand-Abravanel F, Kamar N, Sandres-Saune K et al. Characteristics of autochthonous hepatitis E virus infection in solid-organ transplant recipients in France. J. Infect. Dis. 202(6), 835-844 (2010).
39. Carpentier A, Chaussade H, Rigaud E et al. High hepatitis E virus seroprevalence in forestry workers and in wild boars in France. J. Clin. Microbiol. 50(9), 2888-2893 (2012).
40. Scobie L, Dalton HR. Hepatitis E source and route of infection, clinical manifestations and new developments. J. Viral. Hepat. 20(1), 1-11 (2013).
41. Boxall E, Herborn A, Kochethu G et al. Transfusion-transmitted hepatitis E in a 'nonhyperendemic' country. Transfusion Med. 16(2), 79-83 (2006).
42. Vollmer T, Diekmann J, Johne R, Eberhardt M, Knabbe C, Dreier J. Novel approach for detection of hepatitis E virus infection in German blood donors. J. Clin. Microbiol. 50(8), 2708-2713 (2012).
43. Xu C, Wang RY, Schechterly CA et al. An assessment of hepatitis E virus (HEV) in US blood donors and recipients: no detectable HEV RNA in 1939 donors tested and no evidence for HEV transmission to 362 prospectively followed recipients. Transfusion 53(10 Pt 2), 2505-2511 (2013).
44. Mansuy JM, Bendall R, Legrand-Abravanel F et al. Hepatitis E virus antibody in blood donors, France. Emerging Infect. Dis. 17(12), 2309-2312 (2011).
45. Bendall R, Ellis V, Ijaz S, Ali R, Dalton H. A comparison of two commercially available anti-HEV IgG kits and a re-evaluation of anti-HEV IgG seroprevalence data in developed countries. J. Med. Virol. 82(5), 799-805 (2010).
46. Abravanel F, Chapuy-Regaud S, Lhomme S et al. Performance of anti-HEV assays for diagnosis acute hepatitis E in immunocompromised patients. J. Clin. Virol. 58(4), 624-628 (2013).
47. Beale M, Tettmar K, Szypulska R, Tedder RS, Ijaz S. Is there evidence of recent hepatitis E virus infection in English and North Welsh blood donors? Vox Sang. 100(3), 340-342 (2011).
48. Faramawi MF, Johnson E, Chen S, Pannala PR. The incidence of hepatitis E virus infection in the general population of the USA. Epidemiol. Infect. 139(8), 1145-1150 (2011).
49. Abravanel F, Lhomme S, Chapuy-Regaud S et al. Hepatitis E Virus Reinfections in Solid-Organ-Transplant Recipients Can Evolve Into Chronic Infections. J. Infect. Dis. 209(12), 1900-1906 (2014).
50. Li RC, Ge SX, Li YP et al. Seroprevalence of hepatitis E virus infection, rural southern People's Republic of China. Emerging Infect. Dis. 12(11), 1682-1688 (2006).
51. Kamar N, Bendall R, Legrand-Abravanel F et al. Hepatitis E. Lancet 379, 2477-2488 (2012).
52. Kumar Acharya S, Kumar Sharma P, Singh R et al. Hepatitis E virus (HEV) infection in patients with cirrhosis is associated with rapid decompensation and death. J. Hepatol. 46(3), 387-394 (2007).
53. Rein DB, Stevens GA, Theaker J, Wittenborn JS, Wiersma ST. The global burden of hepatitis E virus genotypes 1 and 2 in 2005. Hepatology 55(4), 988-997 (2012).
54. Labrique AB, Sikder SS, Krain LJ et al. Hepatitis e, a vaccine-preventable cause of maternal deaths. Emerging Infect. Dis. 18(9), 1401-1404 (2012).
55. Teo CG. Fatal outbreaks of jaundice in pregnancy and the epidemic history of hepatitis E. Epidemiol. Infect. 140(5), 767-787 (2012).
56. Dalton HR, Bendall R, Ijaz S, Banks M. Hepatitis E an emerging infection in developed countries. Lancet Infect. Dis. 8(11), 698-709 (2008).
57. Dalton HR, Bendall RP, Rashid M et al. Host risk factors and autochthonous hepatitis E infection. Eur. J. Gastroenterol. Hepatol. 23(12), 1200-1205 (2011).
58. Dalton HR, Stableforth W, Thurairajah P et al. Autochthonous hepatitis E in Southwest England: natural history, complications and seasonal variation, and hepatitis E virus IgG seroprevalence in blood donors, the elderly and patients with chronic liver disease. Eur. J. Gastroenterol. Hepatol. 20(8), 784-790 (2008).
59. Dalton HR, Hazeldine S, Banks M, Ijaz S, Bendall R. Locally acquired hepatitis E in chronic liver disease. Lancet 369(9569), 1260 (2007).
60. Kamar N, Bendall RP, Peron JM et al. Hepatitis E virus and neurologic disorders. Emerging Infect. Dis. 17(2), 173-179 (2011).
61. Dalton HR, Fellows HJ, Stableforth W et al. The role of hepatitis E virus testing in drug-induced liver injury. Aliment Pharmacol. Ther. 26(10), 1429-1435 (2007).
62. Vine LJ, Shepherd K, Hunter JG et al. Characteristics of Epstein-Barr virus hepatitis among patients with jaundice or acute hepatitis. Aliment. Pharmacol. Ther. 36(1), 16-21 (2012).
63. Harvala H, Wong V, Simmonds P, Johannessen I, Ramalingam S. Acute viral hepatitis - should the current screening strategy be modified? J. Clin. Virol. 59(3), 184-187 (2014).
64. Hakze-Van Der Honing RW, Van Coillie E, Antonis AF, Van Der Poel WH. First isolation of hepatitis E virus genotype 4 in Europe through swine surveillance in The Netherlands and Belgium. PLoS ONE 6(8), e22673 (2011).
65. Midgley S, Vestergaard HT, Dalgaard C, Enggaard L, Fischer TK. Hepatitis E virus genotype 4, Denmark, 2012. Emerging Infect. Dis. 20(1), 156-157 (2014).
66. Bouamra Y, Gerolami R, Arzouni JP et al. Emergence of autochthonous infections with hepatitis E virus of genotype 4 in Europe. Intervirology 57(1), 43-48 (2014).
67. Kamar N, Selves J, Mansuy JM et al. Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N. Engl. J. Med. 358(8), 811-817 (2008).
68. Dalton HR, Bendall R, Keane F, Tedder R, Ijaz S. Persistent carriage of hepatitis E virus in patients with HIV infection. N. Engl. J. Med. 361(10), 1025-1027 (2009).
69. Kamar N, Rostaing L, Legrand-Abravanel F, Izopet J. How should hepatitis E virus infection be defined in organ-transplant recipients? Am. J. Transplant. 13(7), 1935-1936 (2013).
70. Kamar N, Garrouste C, Haagsma EB et al. Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants. Gastroenterology 140(5), 1481-1489 (2011).
71. Kamar N, Abravanel F, Selves J et al. Influence of immunosuppressive therapy on the natural history of genotype 3 hepatitis-E virus infection after organ transplantation. Transplantation 89(3), 353-360 (2010).
72. Suneetha PV, Pischke S, Schlaphoff V et al. HEV-specific T-cell responses are associated with control of HEV infection. Hepatology 55(3), 695-708 (2012).
73. Lhomme S, Abravanel F, Dubois M et al. HEV quasispecies and the outcome of acute hepatitis E in solid-organ transplant patients. J. Virol. 86(18), 100006-100014 (2012).
74. Lhomme S, Garrouste C, Kamar N et al. Influence of polyproline region and macro domain genetic heterogeneity on HEV persistence in immunocompromised patients. J. Infect. Dis. 209(2), 300-303 (2013).
75. Kamar N, Izopet J, Cintas P et al. Hepatitis E virus-induced neurological symptoms in a kidney-transplant patient with chronic hepatitis. Am. J. Transplant. 10(5), 1321-1324 (2010).
76. Van Den Berg B, Van Der Eijk AA, Pas SD et al. Guillain-Barre syndrome associated with preceding hepatitis E virus infection. Neurology 82(6), 491-497 (2014).
77. Van Eijk JJ, Madden RG, Van Der Eijk AA et al. Neuralgic amyotrophy and hepatitis E virus infection. Neurology 82(6), 498-503 (2014).
78. Kamar N, Weclawiack H, Guilbeaud-Frugier C et al. Hepatitis E virus and the kidney in solid-organ-transplant patients. Transplantation 93(6), 617-623 (2012).
79. Pischke S, Stiefel P, Franz B et al. Chronic hepatitis E in heart transplant recipients. Am. J. Transplant. 12(11), 3128-3133 (2012).
80. Wang Y, Zhou X, Debing Y et al. Calcineurin inhibitors stimulate and mycophenolic acid inhibits replication of hepatitis E virus. Gastroenterology 146(7), 1775-1783 (2014).
81. Kamar N, Rostaing L, Izopet J. Hepatitis E virus infection in immunosuppressed patients: natural history and therapy. Semin. Liver. Dis. 33(1), 62-70 (2013).
82. Kamar N, Izopet J, Tripon S et al. Ribavirin for chronic hepatitis E virus infection in transplant recipients. N. Engl. J. Med. 370(12), 1111-1120 (2014).
83. Debing Y, Emerson SU, Wang Y et al. Ribavirin inhibits in vitro hepatitis E virus replication through depletion of cellular GTP pools and is moderately synergistic with alpha interferon. Antimicrob. Agents Chemother. 58(1), 267-273 (2014).
84. Kamar N, Izopet J, Rostaing L. No reactivation of hepatitis E virus after kidney retransplantation. Am. J. Transplant. 12(2), 507-508 (2012).
85. Zhu Fc, Zhang J, Zhang XF et al. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, Phase 3 trial. Lancet 376(9744), 895-902 (2010).